Supernus Pharmaceuticals, Inc. (SUPN)
44.21
+0.48
(+1.10%)
USD |
NASDAQ |
Aug 31, 16:00
44.22
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Cash from Operations (TTM) : 19.91M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.91M |
| March 31, 2026 | 83.26M |
| December 31, 2025 | 47.33M |
| September 30, 2025 | 71.88M |
| June 30, 2025 | 187.06M |
| March 31, 2025 | 164.15M |
| December 31, 2024 | 171.95M |
| September 30, 2024 | 172.50M |
| June 30, 2024 | 154.86M |
| March 31, 2024 | 100.36M |
| December 31, 2023 | 111.08M |
| September 30, 2023 | 93.69M |
| June 30, 2023 | 71.66M |
| March 31, 2023 | 161.65M |
| December 31, 2022 | 116.83M |
| September 30, 2022 | 138.02M |
| June 30, 2022 | 120.07M |
| March 31, 2022 | 95.23M |
| December 31, 2021 | 127.13M |
| September 30, 2021 | 110.30M |
| June 30, 2021 | 120.01M |
| March 31, 2021 | 165.68M |
| December 31, 2020 | 138.40M |
| September 30, 2020 | 150.26M |
| June 30, 2020 | 182.32M |
| Date | Value |
|---|---|
| March 31, 2020 | 119.05M |
| December 31, 2019 | 143.13M |
| September 30, 2019 | 132.19M |
| June 30, 2019 | 156.98M |
| March 31, 2019 | 134.85M |
| December 31, 2018 | 128.99M |
| September 30, 2018 | 132.47M |
| June 30, 2018 | 109.03M |
| March 31, 2018 | 128.42M |
| December 31, 2017 | 114.64M |
| September 30, 2017 | 103.24M |
| June 30, 2017 | 92.48M |
| March 31, 2017 | 83.31M |
| December 31, 2016 | 66.81M |
| September 30, 2016 | 64.21M |
| June 30, 2016 | 35.45M |
| March 31, 2016 | 31.65M |
| December 31, 2015 | 34.52M |
| September 30, 2015 | 19.18M |
| June 30, 2015 | 46.49M |
| March 31, 2015 | 26.57M |
| December 31, 2014 | 7.733M |
| September 30, 2014 | -8.682M |
| June 30, 2014 | -51.02M |
| March 31, 2014 | -59.83M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Indivior Pharmaceuticals, Inc. | -48.64M |
| Pfizer Inc. | 13.40B |
| Amphastar Pharmaceuticals, Inc. | 184.61M |
| Collegium Pharmaceutical, Inc. | 329.92M |
| Bristol Myers Squibb Co. | 12.78B |